---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-033358"
form_type: "8-K"
ticker: "AZTR"
cik: "0001701478"
company_name: "Azitra, Inc."
filed_at: "2026-07-15T20:10:42+00:00"
generated_at: "2026-07-15T20:12:16.782977+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Azitra reports ATR-COSF ex vivo results: 4.4-fold elasticity increase, improved distribution

## Summary
- ATR-COSF supernatant with recombinant filaggrin showed increased penetration into stratum granulosum with multiple doses in ex vivo human skin.
- Hydrogel with 7.5% w/w supernatant increased skin elasticity 4.4-fold; 0.28% w/w restored elasticity to healthy skin levels.
- Safety testing confirmed 2% supernatant formulation is non-irritating and non-corrosive to skin and eyes.
- CEO plans to optimize formulations and initiate human study for visible wrinkle reduction.

## SEC filing metadata
- accession: 0001493152-26-033358
- form_type: 8-K
- ticker: AZTR
- cik: 0001701478
- company_name: Azitra, Inc.
- filed_at: 2026-07-15T20:10:42+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701478/000149315226033358/0001493152-26-033358-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701478/000149315226033358/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-033358
- JSON: https://secwatch.observer/filing/0001493152-26-033358.json
- Plain text: https://secwatch.observer/filing/0001493152-26-033358.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.